Rosenbloom: Curb PBMs’ power
By Alan Rosenbloom
Letter to the Editor
The Washington Times
Despite the purported value of pharmacy benefit managers (PBMs), drug prices remain unaffordable for many Americans (“Prescription drug pricing reform must rein in pharmacy benefit managers,” Web, Oct. 18). As middlemen between the manufacturers, pharmacies and consumers, PBMs are notorious for abusive business practices that impact both patients’ wallets and their access to prescription drugs, while gouging unaffiliated pharmacies.
As Rep. Carter and Mr. Wilcox correctly note, PBMs process the vast majority of the nation’s prescription drugs. This undue concentration of market power means they can and do restrict consumer access to expensive drugs and cause delays in treatment, all so that affiliated pharmacies dispense and earn revenues while denying competing pharmacies access to high-margin drugs.
PBMs are not freestanding operations. They are part of huge health care conglomerates that dominate not only the PBM market, but a series of adjoining markets including health insurance, retail pharmacy, specialty pharmacy, mail-order pharmacy and long-term-care pharmacy. They have also become health care providers, which has allowed them to control the flow of medications. This anti-competitive behavior is clearly apparent in Express Scripts’ recent decision to reduce reimbursement rates for pharmacies in the TRICARE network, forcing veterans and their families to find alternate ways to access covered drugs — or simply pay for them out-of-pocket.
Small businesses, such as the community and long-term care pharmacies that are not part of these corporate behemoths, deserve protection from unfair trade practices. Consumers deserve more than the illusion of low costs at the price of easy access to essential medications.
To curb PBMs’ exploitative business practices, all stakeholders — including the Federal Trade Commission, Congress, the Biden administration and federal health departments — must focus on how these entities drive high drug prices, restrict access to essential medications and threaten unaffiliated pharmacies.
To view the original article click here.
Recent Posts
-
Check out SCPC CEO Alan Rosenbloom on the Pharmacy Podcast Network’s “PBM Reform Podcast”
SCPC President and CEO Alan Rosenbloom speaks with the Pharmacy Podcast Network the importance of advocating for PBM reform, the status of the LTC Pharmacy Definition Act, LTC Pharmacy at-home, drug pricing legislation and its implications for LTC Pharmacy, and more.
-
SCPC Applauds House Oversight and Accountability Committee Chair James Comer for Launching Investigation into PBM Practices
The Senior Care Pharmacy Coalition (SCPC), the only Washington-based organization exclusively representing the interests of long-term care (LTC) pharmacies, applauds House Committee on Oversight and Accountability Chairman James Comer (R-KY) for launching an investigation into pharmacy benefit managers (PBMs) and their tactics that are harming patient care and increasing costs for many patients.
-
Senior Care Pharmacy Coalition Provides Comments on Improving Care for Dually Eligible Enrollees
The Senior Care Pharmacy Coalition (SCPC), the only Washington-based organization exclusively representing the interests of long-term care (LTC) pharmacies, has responded to a Request for Information issued by a bipartisan group of Senators led by Senator Bill Cassidy (R-LA) regarding policy recommendations to improve care for enrollees dually eligible for Medicare and Medicaid programs (dual eligibles) and substantially reduce the amount of money both programs otherwise would expect to spend over time.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.